Kesimpta
What Kesimpta is used for
Kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features (see section 5.1).
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Kesimpta
- Active substance
- ofatumumab
- Disease area
- Multiple Sclerosis, Relapsing-Remitting
- Medicine group
- Immunosuppressant
- ATC code
- L04AA52
- Marketing authorisation holder
- Novartis Europharm Limited
- Authorised in the EU since
- 2021
Official information
In the USA
Same active substance: Kesimpta
In India
- Ofatumumab: 2 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Kesimpta used for?
Kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features (see section 5.1).
What is the active substance in Kesimpta?
Kesimpta contains ofatumumab.
Who makes Kesimpta?
The EU marketing authorisation holder is Novartis Europharm Limited.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU